Last reviewed · How we verify
continue the PI/r-containing HAART.
Ritonavir is a protease inhibitor used to treat HIV-1 infection by preventing the replication of the virus.
Ritonavir is a protease inhibitor used to treat HIV-1 infection by preventing the replication of the virus. Used for Treatment of HIV-1 infection in combination with other antiretroviral medications.
At a glance
| Generic name | continue the PI/r-containing HAART. |
|---|---|
| Also known as | the drugs will depend on the successful regimen. |
| Sponsor | ASST Fatebenefratelli Sacco |
| Drug class | Protease inhibitor |
| Target | HIV-1 protease |
| Modality | Small molecule |
| Therapeutic area | Infectious disease |
| Phase | Phase 3 |
Mechanism of action
Ritonavir works by binding to the protease enzyme of the HIV-1 virus, preventing it from processing viral proteins and replicating the virus. This results in a decrease in the viral load and an increase in the CD4 cell count. Ritonavir is often used in combination with other antiretroviral medications to achieve optimal treatment outcomes.
Approved indications
- Treatment of HIV-1 infection in combination with other antiretroviral medications
Common side effects
- Nausea
- Diarrhea
- Fatigue
- Headache
- Abdominal pain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- continue the PI/r-containing HAART. CI brief — competitive landscape report
- continue the PI/r-containing HAART. updates RSS · CI watch RSS
- ASST Fatebenefratelli Sacco portfolio CI